Quick Answer
Aclaris Therapeutics, Inc. reported Operating Income Loss of -$76.38 million for the year ending 2025.
- Aclaris Therapeutics, Inc. showed an increase of +46.2% in Operating Income Loss from 2024 to 2025.
- This data is from Aclaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$2.63 million | Q2 2015: -$2.60 million | Q3 2015: -$10.64 million | Q1 2016: -$13.14 million | Q2 2016: -$12.99 million | Q3 2016: -$10.81 million | Q1 2017: -$12.93 million | Q2 2017: -$15.30 million | Q3 2017: -$18.76 million | Q1 2018: -$30.95 million | Q2 2018: -$31.98 million | Q3 2018: -$21.34 million | Q1 2019: -$27.05 million | Q2 2019: -$43.60 million | Q3 2019: -$22.86 million | Q1 2020: -$15.51 million | Q2 2020: -$11.38 million | Q3 2020: -$10.47 million | Q1 2021: -$28.53 million | Q2 2021: -$18.01 million | Q3 2021: -$20.30 million | Q1 2022: -$18.91 million | Q2 2022: -$20.99 million | Q3 2022: -$20.87 million | Q1 2023: -$29.92 million | Q2 2023: -$31.82 million | Q3 2023: -$31.58 million | Q1 2024: -$18.93 million | Q2 2024: -$12.85 million | Q3 2024: -$10.47 million | Q1 2025: -$18.08 million | Q2 2025: -$18.41 million | Q3 2025: -$17.15 million.
- Over the full 13 years of available data (2013 to 2025), Aclaris Therapeutics, Inc.'s Operating Income Loss has declined by 1,352.8%.
- Historical annual values: Fiscal year 2025: -$76.38 million | Fiscal year 2024: -$141.93 million | Fiscal year 2023: -$97.36 million | Fiscal year 2022: -$89.85 million | Fiscal year 2021: -$89.72 million | Fiscal year 2020: -$50.91 million | Fiscal year 2019: -$111.06 million | Fiscal year 2018: -$84.78 million | Fiscal year 2017: -$54.36 million | Fiscal year 2016: -$48.57 million | Fiscal year 2015: -$20.67 million | Fiscal year 2014: -$8.53 million | Fiscal year 2013: -$5.26 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: